By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Delcath Systems, Inc. 

1100 Summer Street, 3rd Floor

Stamford  Connecticut  06905  U.S.A.
Phone: 203-323-8668 Fax: 203-961-0120


Drug Delivery

Company News
Delcath Systems (DCTH) Receives Orphan Drug Designation From FDA For Melphalan To Treat Cholangiocarcinoma 7/20/2015 7:47:04 AM
Delcath Systems (DCTH) Announces Pricing Of Public Offering 7/16/2015 11:26:40 AM
Delcath Systems (DCTH) Announces Acceptance Of Abstracts For Presentation At The Cardiovascular And Interventional Radiology Society Annual Meeting 6/9/2015 10:14:10 AM
Delcath Systems (DCTH) To Webcast Management's Presentation At Annual Meeting Of Shareholders On June 10, 2015 6/5/2015 6:53:52 AM
ASCO15: Positive Data With Delcath Systems (DCTH)'s CHEMOSAT Highlighted At ASCO 2015 5/29/2015 7:21:34 AM
Delcath Systems (DCTH)'s European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer Patients 5/27/2015 9:59:55 AM
Delcath Systems (DCTH) Names Dr. Jennifer Simpson President And CEO 5/26/2015 7:36:12 AM
ICC Cohort Of Delcath Systems (DCTH)'s Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment 5/21/2015 6:41:35 AM
Delcath Systems (DCTH) Reports 2015 First Quarter Financial Results 5/7/2015 7:59:59 AM
Delcath Systems (DCTH) Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4/21/2015 11:30:54 AM